BridgeBio Pharma
ISIN US10806X1028
|WKN A2PLX7
Overview
Description
BridgeBio Pharma, Inc. engages in identifying and advancing transformative medicines to treat patients who suffer from Mendelian diseases. Its pipeline of development programs includes product candidates ranging from early discovery to late-stage development. The company was founded by Charles Homcy, Francis Patrick McCormick, Philip Reilly, and Neil Kumar in 2015 and is headquartered in Palo Alto, CA.
Healthcare Biopharmaceuticals System-Specific Biopharmaceuticals United States
Financials
Key metrics
| Market capitalisation, EUR | 5,675.25 m |
| EPS, EUR | -2.63 |
| P/B ratio | - |
| P/E ratio | - |
| Dividend yield | 0.00% |
Income statement (2024)
| Revenue, EUR | 205.14 m |
| Net income, EUR | -495.30 m |
| Profit margin | -241.44% |
What ETF is BridgeBio Pharma in?
There are 28 ETFs which contain BridgeBio Pharma. All of these ETFs are listed in the table below. The ETF with the largest weighting of BridgeBio Pharma is the WisdomTree BioRevolution UCITS ETF USD Acc.
— Data provided by Trackinsight, etfinfo, Xignite Inc., gettex, FactSet and justETF GmbH.
Quotes are either real-time (gettex) or 15 minutes delayed stock exchange quotes or NAVs (daily published by the fund provider). By default, ETF returns include dividend payments (if applicable). There is no warranty for completeness, accuracy and correctness for the displayed information.
Quotes are either real-time (gettex) or 15 minutes delayed stock exchange quotes or NAVs (daily published by the fund provider). By default, ETF returns include dividend payments (if applicable). There is no warranty for completeness, accuracy and correctness for the displayed information.
